| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Acetazolamide — Acetazolamide is a synthetic small-molecule sulfonamide drug (classical carbonic anhydrase inhibitor; CAI) used clinically for glaucoma, altitude sickness/AMS prophylaxis, edema, and as an adjunct in some seizure disorders. It is a small-molecule drug modality (repurposed-drug context for oncology discussions), commonly abbreviated AZM and marketed historically as Diamox. In cancer-biology framing, interest centers on inhibiting tumor-associated carbonic anhydrase isoforms (notably CA IX/CA XII in hypoxic tumors) to perturb tumor pH control and thereby modulate invasion, therapy resistance, and microenvironmental immunosuppression. Primary mechanisms (ranked):
Bioavailability / PK relevance: Orally and IV administered; distributes broadly with notable intraerythrocytic distribution and meaningful plasma protein binding; largely renally eliminated. Dose-limiting pharmacology is carbonic-anhydrase–driven bicarbonaturia with risks of metabolic acidosis and electrolyte disturbance, which constrains escalation for oncology repurposing. In-vitro vs systemic exposure relevance: Enzyme inhibition is concentration-driven and can be achieved systemically at therapeutic exposures, but anti-tumor effects reported in models often depend on tumor context (hypoxia/CA IX-high, acid-base transporter landscape) and may use exposures or schedules not directly matched to standard clinical dosing; translation is therefore context- and dosing-limited. Clinical evidence status: Established, approved drug for non-oncology indications; oncology use remains investigational (preclinical and limited early clinical combinations/adjunct concepts). No major guideline-positioned anticancer indication as monotherapy; most oncology rationale is microenvironment/pH targeting and combination sensitization. Acetazolamide might impact cancer biology:Carbonic Anhydrase Inhibition • Acetazolamide inhibits several isoforms of carbonic anhydrase (CA IX and CA XII), enzymes that catalyze the reversible hydration of carbon dioxide to bicarbonate and protons. • In many cancers, CA IX is overexpressed in response to hypoxia (mediated by HIF‐1α) and helps maintain an acidic extracellular environment while keeping the intracellular pH relatively neutral. This pH regulation supports cancer cell survival and invasion. Tumor pH Regulation • By inhibiting carbonic anhydrases, acetazolamide can disrupt the acid–base balance in the tumor microenvironment. • An altered pH gradient can impair cancer cell proliferation, migration, invasion, and can influence drug resistance. This disruption may also sensitize tumors to other therapeutic modalities. Hypoxia and HIF-1 Signaling • Inhibiting CA IX may indirectly affect downstream targets of the HIF-1 pathway, potentially interfering with processes such as angiogenesis and metabolic adaptation. Impact on Tumor Metabolism • The inhibition of carbonic anhydrases may affect the metabolic reprogramming seen in cancer cells. • Alterations in bicarbonate and proton handling can influence metabolic pathways like glycolysis and oxidative phosphorylation, which are often altered in tumor cells. Potential Effects on Immune Response • An acidic tumor microenvironment can contribute to immunosuppression. • By modifying the pH environment through the inhibition of carbonic anhydrase, acetazolamide might help improve immune cell infiltration and function, although this area is still under investigation. In summary, while acetazolamide is a synthetic drug and not a natural product, its ability to alter key aspects of tumor biology—such as pH regulation, hypoxia response, and metabolic reprogramming—makes it an interesting candidate for adjuvant cancer therapies. However, its application in oncology remains investigational and would require further clinical validation. Acetazolamide — mechanistic axes relevant to oncology (contextual repurposing)
|
| Source: TCGA |
| Type: Antiapoptotic |
| Nrf2 is responsible for regulating an extensive panel of antioxidant enzymes involved in the detoxification and elimination of oxidative stress. Thought of as "Master Regulator" of antioxidant response. -One way to estimate Nrf2 induction is through the expression of NQO1. NQO1, the most potent inducer: SFN 0.2 μM, quercetin (2.5 μM), curcumin (2.7 μM), Silymarin (3.6 μM), tamoxifen (5.9 μM), genistein (6.2 μM ), beta-carotene (7.2μM), lutein (17 μM), resveratrol (21 μM), indol-3-carbinol (50 μM), chlorophyll (250 μM), alpha-cryptoxanthin (1.8 mM), and zeaxanthin (2.2 mM) 1. Raising Nrf2 enhances the cell's antioxidant defenses and ↓ROS. This strategy is used to decrease chemo-radio side effects. 2. Downregulating Nrf2 lowers antioxidant defenses and ↑ROS. In cancer cells this leads to DNA damage, and cell death. 3. However there are some cases where increasing Nrf2 paradoxically causes an increase in ROS (cancer cells). Such as cases of Mitochondial overload, signal crosstalk, reductive stress -In some cases, Nrf2 is overexpressed in cancer cells, which can lead to the activation of genes involved in cell proliferation, angiogenesis, and metastasis. This can contribute to the development of resistance to chemotherapy and targeted therapies. -Increased Nrf2 expression: Lung, Breast, Colorectal, Prostrate. Decreased Nrf2 expression: Skine, Liver, Pancreatic. -Nrf2 is a cytoprotective transcription factor which demonstrated both a negative effect as well as a positive effect on cancer - "promotes Nrf2 translocation from the cytoplasm to the nucleus," means facilitates the movement of Nrf2 into the nucleus, thereby enhancing the cell's antioxidant and cytoprotective responses. -Major regulator of Nrf2 activity in cells is the cytosolic inhibitor Keap1. Nrf2 Inhibitors and Activators Nrf2 Inhibitors: Brusatol, Luteolin, Trigonelline, VitC, Retinoic acid, Chrysin Nrf2 Activators: SFN, OPZ EGCG, Resveratrol, DATS, CUR, CDDO, Api - potent Nrf2 inducers from plants include sulforaphane, curcumin, EGCG, resveratrol, caffeic acid phenethyl ester, wasabi, cafestol and kahweol (coffee), cinnamon, ginger, garlic, lycopene, rosemany Nrf2 plays dual roles in that it can protect normal tissues against oxidative damage and can act as an oncogenic protein in tumor tissue. – In healthy tissues, NRF2 activation helps protect cells from oxidative damage and maintains cellular homeostasis. – In many cancers, constitutive activation of NRF2 (often through mutations in NRF2 itself or loss-of-function mutations in KEAP1) leads to an enhanced antioxidant capacity. – This upregulation can promote tumor cell survival by enabling cancer cells to thrive under oxidative stress, resist chemotherapeutic agents, and sustain metabolic reprogramming. – Elevated NRF2 levels have been implicated in promoting tumor growth, metastasis, and resistance to therapy in various malignancies. – High or sustained NRF2 activity is frequently associated with aggressive tumor phenotypes, poorer prognosis, and decreased overall survival in several cancer types. – While its activation is essential for protecting normal cells from oxidative stress, aberrant or sustained NRF2 activation in tumor cells can lead to enhanced survival, therapeutic resistance, and tumor progression. NRF2 inhibitors: (to decrease antioxidant defenses and increase cell death from ROS). -Brusatol: most cited natural inhibitors of Nrf2. -Luteolin: luteolin can reduce Nrf2 activity in specific cancer models and may enhance cell sensitivity to chemotherapy. However, luteolin is also known as an antioxidant, and its influence on Nrf2 can sometimes be context dependent. -Apigenin: certain studies to down‑regulate Nrf2 in cancer cells: Dose and context dependent . -Oridonin: -Wogonin: although its effects might be cell‑ and dose‑specific. - Withaferin A |
| - | in-vitro, | BrCC, | H720 | - | in-vivo, | BrCC, | NA | - | in-vitro, | BrCC, | H727 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:277 Target#:226 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid